{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:28:05Z","timestamp":1791908885547,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.vaccine.2017.10.112","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T15:05:55Z","timestamp":1518188755000},"page":"3124-3133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["High-cell-density cultivations to increase MVA virus production"],"prefix":"10.1016","volume":"36","author":[{"given":"Daniel","family":"V\u00e1zquez-Ram\u00edrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Genzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Sandig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Reichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.10.112_b0005","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified Vaccinia Virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses-Basel"},{"key":"10.1016\/j.vaccine.2017.10.112_b0010","first-page":"24","article-title":"Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures","volume":"195","author":"Mayr","year":"1964","journal-title":"Zentralbl Bakteriol Orig"},{"key":"10.1016\/j.vaccine.2017.10.112_b0015","doi-asserted-by":"crossref","unstructured":"Rimmelzwaan GF, Kreijtz JHCM, Suezer Y, Schwantes A, Osterhaus ADME, Sutter G. Preclinical evaluation of influenza vaccines based on replication-deficient poxvirus vector MVA. Procedia Vaccinol 2011;4.","DOI":"10.1016\/j.provac.2011.07.011"},{"key":"10.1016\/j.vaccine.2017.10.112_b0020","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1016\/j.vaccine.2015.04.086","article-title":"Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: a quantitative key opinion leader analysis","volume":"33","author":"Ramezanpour","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.112_b0025","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.vaccine.2013.03.016","article-title":"Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies","volume":"31","author":"Volz","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.112_b0030","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1586\/14760584.2013.845531","article-title":"Clinical applications of attenuated MVA poxvirus strain","volume":"12","author":"Gomez","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.10.112_b0035","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of Modified Vaccinia virus Ankara vaccines","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.112_b0040","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.vaccine.2012.02.015","article-title":"Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines","volume":"30","author":"Hess","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.112_b0045","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4161\/hv.20778","article-title":"Poxvirus vectors as HIV\/AIDS vaccines in humans","volume":"8","author":"Gomez","year":"2012","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2017.10.112_b0050","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.4161\/hv.21689","article-title":"Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines","volume":"8","author":"Boukhebza","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2017.10.112_b0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/156652311795684731","article-title":"MVA and NYVAC as vaccines against emergent infectious diseases and cancer","volume":"11","author":"Gomez","year":"2011","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.vaccine.2017.10.112_b0060","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.vaccine.2008.11.066","article-title":"An avian cell line designed for production of highly attenuated viruses","volume":"27","author":"Jordan","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.112_b0065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.biologicals.2010.11.005","article-title":"A chemically defined production process for highly attenuated poxviruses","volume":"39","author":"Jordan","year":"2011","journal-title":"Biologicals"},{"issue":"Suppl 8","key":"10.1016\/j.vaccine.2017.10.112_b0070","doi-asserted-by":"crossref","first-page":"O1","DOI":"10.1186\/1753-6561-5-S8-O1","article-title":"Highly efficient, chemically defined and fully scalable biphasic production of vaccine viruses","volume":"5","author":"Jordan","year":"2011","journal-title":"BMC Proc"},{"key":"10.1016\/j.vaccine.2017.10.112_b0075","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/j.vaccine.2009.05.083","article-title":"New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation","volume":"27","author":"Lohr","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.112_b0080","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/v5010321","article-title":"A genotype of Modified Vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium","volume":"5","author":"Jordan","year":"2013","journal-title":"Viruses-Basel"},{"key":"10.1016\/j.vaccine.2017.10.112_b0085","doi-asserted-by":"crossref","DOI":"10.1007\/s00253-015-7267-9","article-title":"Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production","author":"Tapia","year":"2016","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2017.10.112_b0090","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/bit.20074","article-title":"Insights into adenoviral vector production kinetics in acoustic filter-based perfusion cultures","volume":"86","author":"Henry","year":"2004","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2017.10.112_b0095","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0734-9750(02)00030-7","article-title":"Production of adenovirus vector for gene therapy","volume":"20","author":"Nadeau","year":"2003","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2017.10.112_b0100","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/bit.260390605","article-title":"Quantification of cell-culture factors affecting recombinant protein yields in baculovirus-infected insect cells","volume":"39","author":"Lindsay","year":"1992","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2017.10.112_b0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/bit.10773","article-title":"Virus-like particle production at low multiplicities of infection with the baculovirus insect cell system","volume":"84","author":"Maranga","year":"2003","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2017.10.112_b0110","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/j.vaccine.2014.02.016","article-title":"High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells","volume":"32","author":"Genzel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.112_b0115","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/bit.20158","article-title":"Perfusion cultures of human tumor cells: a scalable production platform for oncolytic adenoviral vectors","volume":"86","author":"Yuk","year":"2004","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2017.10.112_b0120","unstructured":"Van HH, Luitjens A. Method for the production of ad26 adenoviral vectors. Google Patents; 2011."},{"key":"10.1016\/j.vaccine.2017.10.112_b0125","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.vaccine.2013.11.044","article-title":"Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor","volume":"32","author":"Tapia","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.112_b0130","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/bit.20947","article-title":"Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor","volume":"95","author":"Ghani","year":"2006","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2017.10.112_b0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF00353919","article-title":"Engineering challenges in high density cell culture systems","volume":"22","author":"Ozturk","year":"1996","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2017.10.112_b0140","doi-asserted-by":"crossref","unstructured":"Kompala DS, Ozturk SS. Optimization of high cell density perfusion bioreactors. In: Ozturk SS, Hu WS, editors. Cell culture technology for pharmaceutical and cell-based therapies. Boca Raton, FL: CRC Press, Taylor & Francis Group; 2006. p. 387\u2013416.","DOI":"10.1201\/9780849351068.ch11"},{"key":"10.1016\/j.vaccine.2017.10.112_b0145","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1472-6750-14-72","article-title":"The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis","volume":"14","author":"Lohr","year":"2014","journal-title":"Bmc Biotechnol"},{"key":"10.1016\/j.vaccine.2017.10.112_b0150","unstructured":"Lohr V. Characterization of the avian designer cells AGE1.CR and AGE1.CR.pIX considering growth, metabolism and production of influenza virus and Modified Vaccinia Virus Ankara (MVA). Magdeburg, Germany: Otto von Guericke University Magdeburg; 2014."},{"key":"10.1016\/j.vaccine.2017.10.112_b0155","doi-asserted-by":"crossref","unstructured":"Lohr V, Genzel Y, Jordan I, Katinger D, Mahr S, Sandig V, et al. Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells. Bmc Biotechnol 2012;12.","DOI":"10.1186\/1472-6750-12-79"},{"key":"10.1016\/j.vaccine.2017.10.112_b0160","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s10529-013-1203-9","article-title":"Oxygen supply in disposable shake-flasks: prediction of oxygen transfer rate, oxygen saturation and maximum cell concentration during aerobic growth","volume":"35","author":"Schiefelbein","year":"2013","journal-title":"Biotechnol Lett"},{"key":"10.1016\/j.vaccine.2017.10.112_b0165","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.vaccine.2008.01.032","article-title":"Development and optimisation of a procedure for the production of Parapoxvirus ovis by large-scale microcarrier cell culture in a non-animal, non-human and non-plant-derived medium","volume":"26","author":"Pohlscheidt","year":"2008","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18300653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18300653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T23:06:00Z","timestamp":1668639960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18300653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":33,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0264410X18300653"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.112","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-cell-density cultivations to increase MVA virus production","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}